快速診斷市場、機會、成長動力、產業趨勢分析與預測，2024-2032

2023 年，全球快速診斷市場估值為 227 億美元，在早期疾病檢測需求不斷成長和慢性病患病率上升的推動下，2024 年至 2032 年複合年成長率將達到 9.2%。隨著醫療保健轉向主動式管理和早期干預，對快速、準確的診斷工具的需求變得更加重要。糖尿病和心血管疾病等慢性病的激增增加了對高效且易於使用的診斷解決方案的需求。對及時檢測和有效管理的綜合需求將顯著擴大市場規模。

快速診斷產業根據購買、配銷通路、產品、技術/平台、最終用途和地區而分散。

由於傳染病檢測在控制疾病爆發和管理公共衛生方面發揮關鍵作用，因此到 2023 年，其市場佔有率將達到 25.6%。隨著全球感染人數的增加以及對即時、準確結果的需求，傳染病的快速診斷檢測變得越來越重要。測試技術的創新和早期檢測意識的提高進一步推動了該領域的成長。隨著對及時有效的診斷解決方案的需求持續成長，傳染病檢測將引領市場。

2023 年，OTC 檢測領域的銷售額為 149 億美元，這歸因於其便利性以及消費者對家庭健康管理日益成長的偏好。非處方藥測試為各種健康狀況提供即時、方便的解決方案，無需醫療保健提供者就診。對個人化醫療保健和自我監測的日益關注，加上方便用戶使用的測試技術的進步，正在推動這一領域的擴張。隨著對易於使用且高效的診斷工具的需求增加，OTC 測試將主導市場。

北美快速診斷市場規模在2023 年達到113 億美元，在其先進的醫療基礎設施、對創新診斷解決方案的高需求以及對醫療技術的大量投資的推動下，到2032 年將以8.2% 的年複合成長率成長。該地區對早期疾病檢測和個人化醫療保健的關注推動了快速診斷測試的採用。此外，強力的醫療政策和慢性病的高發生率也有助於市場成長。北美完善的醫療保健系統和技術進步使其成為快速診斷行業的顯著貢獻者。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 傳染病病率增加
    • 技術進步
    • 快速診斷測試日益普及
    • 人們對早期診斷的認知不斷提高
    • 增加政府在傳染病診斷上的舉措
  • 產業陷阱與挑戰
    • 結果準確度低
    • 替代產品的可用性
    • 嚴格的監管框架
• 成長潛力分析
• 報銷場景
• 監管環境
  • 美國
  • 歐洲
• 技術景觀
• 新興療法
• 差距分析
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按產品分類，2021 - 2032 年

• 主要趨勢
• 傳染病檢測
  • 呼吸道感染檢測產品
  • 流感
  • 肝炎
  • 愛滋病
  • 其他傳染病測試
• 血糖監測
• 心臟代謝測試
• 凝血檢測產品
• 懷孕和生育力測試
• 腫瘤/癌症標記檢測產品
• 尿液分析檢測產品
• 膽固醇檢測產品
• 血液學檢測產品
• 濫用藥物 (DoA) 檢測產品
• 糞便隱匿性檢測產品
• 其他產品

第 6 章：市場估計與預測：按購買方式，2021 - 2032 年

• 主要趨勢
• 場外交易
• 基於處方的測試

第 7 章：市場估計與預測：按技術/平台分類，2021 - 2032

• 流通式
• 固相
• 側流
• 凝集試驗
• 其他技術

第 8 章：市場估計與預測：按配銷通路，2021 - 2032 年

• 醫院藥房
• 磚塊和灰漿
• 電子商務
• 其他分銷管道

第 9 章：市場估計與預測：按最終用途，2021 - 2032 年

• 診斷中心
• 家庭護理設置
• 醫院和診所
• 其他最終用戶

第 10 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 11 章：公司簡介

• Abbott Laboratories
• ACON Laboratories Inc.
• Alfa Scientific Designs Inc.
• Artron Laboratories Inc.
• Becton, Dickinson and Company
• BioMerieux
• Bio-Rad Laboratories
• Danaher Corporation (HemoCue and Radiometer)
• Hologic
• McKesson Medical-Surgical, Inc.
• Meridian Bioscience, Inc.
• QIAGEN NV
• Quidel Corporation
• F. Hoffmann-La Roche Ltd.
• Sight Diagnostics Ltd.
• Trinity Biotech

The Global Rapid Diagnostics Market was valued at USD 22.7 billion in 2023 and will expand to a 9.2% CAGR from 2024 to 2032, propelled by the increasing demand for early disease detection and the rising prevalence of chronic diseases. As healthcare shifts towards proactive management and early intervention, the need for quick, accurate diagnostic tools becomes more critical. The surge in chronic conditions, such as diabetes and cardiovascular diseases, amplifies the demand for efficient and accessible diagnostic solutions. This combined demand for timely detection and effective management will significantly boost the market's size.

The rapid diagnostics industry is fragmented based on purchase, distribution channel, product, technology/platform, end use , and region.

The infectious disease testing segment achieved a 25.6% share in 2023 due to its critical role in controlling disease outbreaks and managing public health. With the rise in global infections and the need for immediate, accurate results, rapid diagnostic tests for infectious diseases are increasingly essential. Innovations in testing technology and heightened awareness of early detection further drive this segment's growth. As the demand for timely and efficient diagnostic solutions continues, infectious disease testing will lead the market.

The OTC testing segment held USD 14.9 billion in 2023, attributed to its convenience and growing consumer preference for at-home health management. OTC tests offer immediate, accessible solutions for various health conditions without the need for a healthcare provider visit. The increasing focus on personalized healthcare and self-monitoring, coupled with advancements in user-friendly testing technologies, is driving the expansion of this segment. As demand for accessible and efficient diagnostic tools rises, OTC testing will dominate the market.

North America rapid diagnostics market size was exhibited at USD 11.3 billion in 2023 and will grow at an 8.2% CAGR through 2032, driven by its advanced healthcare infrastructure, high demand for innovative diagnostic solutions, and substantial investments in medical technology. The region's focus on early disease detection and personalized healthcare drives the adoption of rapid diagnostic tests. Additionally, strong healthcare policies and a high rate of chronic disease contribute to market growth. North America's well-established healthcare system and technological advancements make it a notable contributor to the rapid diagnostics industry.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of infectious disease
    • 3.2.1.2 Technological advancements
    • 3.2.1.3 Increasing popularity of rapid diagnostic tests
    • 3.2.1.4 Rising awareness regarding early diagnosis among people
    • 3.2.1.5 Increasing government initiatives for the diagnosis of infectious diseases
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Low accuracy of results
    • 3.2.2.2 Availability of substitute products
    • 3.2.2.3 Stringent regulatory framework
• 3.3 Growth potential analysis
• 3.4 Reimbursement scenario
• 3.5 Regulatory landscape
  • 3.5.1 U.S.
  • 3.5.2 Europe
• 3.6 Technological landscape
• 3.7 New emerging therapies
• 3.8 GAP analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Infectious disease testing
  • 5.2.1 Respiratory infection testing products
  • 5.2.2 Influenza
  • 5.2.3 Hepatitis
  • 5.2.4 HIV
  • 5.2.5 Other infectious disease tests
• 5.3 Glucose monitoring
• 5.4 Cardiometabolic testing
• 5.5 Coagulation testing products
• 5.6 Pregnancy and fertility testing
• 5.7 Tumor/Cancer marker testing products
• 5.8 Urinalysis testing products
• 5.9 Cholesterol testing products
• 5.10 Hematology testing products
• 5.11 Drug-of-abuse (DoA) testing products
• 5.12 Fecal occult testing products
• 5.13 Other products

Chapter 6 Market Estimates and Forecast, By Purchase, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 OTC
• 6.3 Prescription-based tests

Chapter 7 Market Estimates and Forecast, By Technology/Platform, 2021 - 2032 ($ Mn)

• 7.1 Flow-through
• 7.2 Solid phase
• 7.3 Lateral flow
• 7.4 Agglutination assays
• 7.5 Other technologies

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Hospital pharmacies
• 8.2 Brick and mortar
• 8.3 E-commerce
• 8.4 Other distribution channels

Chapter 9 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 9.1 Diagnostic centers
• 9.2 Homecare settings
• 9.3 Hospitals and clinics
• 9.4 Other end users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Abbott Laboratories
• 11.2 ACON Laboratories Inc.
• 11.3 Alfa Scientific Designs Inc.
• 11.4 Artron Laboratories Inc.
• 11.5 Becton, Dickinson and Company
• 11.6 BioMerieux
• 11.7 Bio-Rad Laboratories
• 11.8 Danaher Corporation (HemoCue and Radiometer)
• 11.9 Hologic
• 11.10 McKesson Medical-Surgical, Inc.
• 11.11 Meridian Bioscience, Inc.
• 11.12 QIAGEN N.V.
• 11.13 Quidel Corporation
• 11.14 F. Hoffmann-La Roche Ltd.
• 11.15 Sight Diagnostics Ltd.
• 11.16 Trinity Biotech